Login / Register The Most Trusted Name in Medical Education

RAISING THE BAR BY LOWERING THE TARGET Integrating PCSK9 Inhibitors into Hypercholesterolemia Management

RAISING THE BAR BY LOWERING THE TARGET Integrating PCSK9 Inhibitors into Hypercholesterolemia Management

Format: Resource Center
Credits: 0.25 AMA PRA Category 1 Credit™ per module

This CME-accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia.

During these quick-hitting activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9). Physicians can complete all 7 video modules for a total of 2.0 AMA PRA Category 1 Credits™. 

Take Course »